| dc.contributor.author | Rueda, Juan D. | |
| dc.contributor.author | Rosselli, Diego | |
| dc.contributor.author | Ruiz, Juan G. | |
| dc.date.accessioned | 2015-12-06T17:25:57Z | |
| dc.date.accessioned | 2016-01-21T02:10:37Z | |
| dc.date.accessioned | 2017-04-19T17:13:39Z | |
| dc.date.accessioned | 2017-06-17T19:44:47Z | |
| dc.date.available | 2015-12-06T17:25:57Z | |
| dc.date.available | 2016-01-21T02:10:37Z | |
| dc.date.available | 2017-04-19T17:13:39Z | |
| dc.date.available | 2017-06-17T19:44:47Z | |
| dc.date.issued | 2013-12 | |
| dc.identifier.issn | 0120-3576 | |
| dc.identifier.uri | http://hdl.handle.net/11445/267 | |
| dc.description | Se diseñó un árbol de decisión para comparar palivizumab con no profilaxis, desde la perspectiva del sistema de salud colombiano, empleando dos horizontes temporales: la infección aguda o toda la vida del paciente. La efectividad fue evaluada en costo por muerte evitada, hospitalización evitada y casos de asma evitados, así como en años de vida ajustados por calidad ganados (AVAC). | |
| dc.description.abstract | We designed a decision tree model comparing palivizumab against no prophylaxis, from the Colombian healthcare system perspective, with two different time horizons: acute infection phase and lifetime follow up. Effectiveness outcomes considered were deaths avoided, hospitalizations and asthma cases averted, as well as quality adjusted life years (QALYs) gained. | |
| dc.subject | Palivizumab | |
| dc.subject | Virus Sincitial Respiratorio | |
| dc.subject | Recién Nacidos Prematuros | |
| dc.subject | Análisis de Costo-Efectividad | |
| dc.subject | Asma | |
| dc.title | Cost-effectiveness of Respiratory Syncytial Virus Infection (RSV) prophylaxis with palivizumab in preterm infants in Colombia | |
| dc.description.jel | I12 | |
| dc.description.jel | I18 | |
| dc.description.jel | I13 | |
| dc.archivo | Co_Eco_Sem2_2013_Rueda_Rosselli_y_Ruiz.pdf | |
